Welcome and Introductions (ID 5004)
Immunotherapy in NSCLC – Where Are We in 2021? (ID 5005)
Why Do We Need Another PD-1 Inhibitor? (ID 5006)
Tislelizumab: The Backbone of Future Immunotherapy Combinations (ID 5008)
What Comes Next? TIGIT, TIM3, OX40 Combinations (ID 5010)
Concluding Remarks (ID 5011)